About

Predict Cancer Risk

Proteocyte’s mission is to provide healthcare professionals with more insightful, objective, and quantifiable data, to significantly improve patient outcomes. Founded in 2011, we are developing a platform of solutions to predict cancer risk, leveraging key biomarkers to dig deeper with proprietary algorithms, advanced imaging, and digital pathology to predict individual risk.

Proteocyte’s first product, Straticyte™, predicts the progression of precancerous oral lesions (OPMD) to invasive cancer (OSCC), across a 5-year span. Straticyte’s ability to ‘look deeper and see farther’ enables healthcare professionals to customize patient management and treatment, offering peace of mind and a path forward.

Sign up, read up, stay informed!

Join our mailing list to stay up-to-date with the latest news and activities from Proteocyte.

Thank you for subscribing to our newsletter!